Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29072096 | 1.00 | NOD1 (0.43) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL29072117 | 0.94 | NOD1 (0.48) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL29072118 | 0.94 | NOD1 (0.48) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL24630046 | 0.94 | NOD1 (0.48) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL29335571 | 0.93 | NOD1 (0.50) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL30634501 | 0.86 | SLC6A5 (0.53) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL17381376 | 0.85 | SLC6A5 (0.55) | NOD1FOLH1GNPATC3AR1SLC6A5 | |
| SCHEMBL17481432 | 0.85 | NOD1 (0.63) | NOD1SLC6A5 | |
| SCHEMBL18089437 | 0.84 | NOD1 (0.66) | NOD1SLC6A5 | |
| SCHEMBL23695804 | 0.84 | SLC6A5 (0.57) | NOD1FOLH1GNPATC3AR1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-116744944-A | Low-immunogenicity biotherapeutic medicine | 奥斯普瑞生物制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | NOD1 3757/4885FOLH1 361/4885GNPAT 872/4885 |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | NOD1 1286/4885FOLH1 614/4885GNPAT 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.